ProCE Banner Activity

TRANSCEND NHL 001: Phase I Study of Lisocabtagene Maraleucel in R/R LBCL

Slideset Download
Conference Coverage

In the pivotal phase I TRANSCEND NHL 001 study, the CD19-directed CAR T-cell therapy lisocabtagene maraleucel demonstrated robust activity and manageable safety in relapsed/refractory LBCL.

Released: December 12, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company